Niels Behrendt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Niels behrendt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Niels Behrendt Today - Breaking & Trending Today
/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of. ....
Adcendo Appoints Michael Pehl as Chief Executive Officer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Adcendo, a Copenhagen, Denmark-based biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers, raised EUR 51m (US$ 62m) in Series A financing. The round was led by Novo Seeds and Ysios Capital, with participation from RA Capital Management, HealthCap and Gilde Healthcare. As part of the financing, Jeroen Bakker, Principal at Novo Seeds, will join the Board. The company plans to use the funds to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in patients. Founded in 2017 by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen, and Henrik Stage, a biotech-entrepreneur active in several biotech companies, and previously CEO/CFO of Santaris Pharma which was acquired by Roche in 2014, Adcendo is developing novel antibody-drug conjugates (ADCs) for treatment of cancers. ADCs are a class of highl ....
Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII). The new financing, which is the largest Series A financing for a Danish biotech company, will be used to establish a pipeline of ADCs directed at novel cancer targets and to bring the lead program targeting the novel cancer target uPARAP/Endo180 to proof of concept in patients. ....
Novo Seeds co-leads Adcendo s EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers - Novo Seeds played instrumental role in supporting Adcendo from inception - Plans to build a pipeline of ADCs directed at novel cancer targets COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers. The EUR 51 million (US$ 62 million) Series A financing was led by Novo Seeds and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. ....